Melanie Zupancic1, Aman Mahajan, Kamna Handa. 1. Department of Internal Medicine, Division Medicine/Psychiatry, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
Abstract
OBJECTIVE: The purpose of this review is to aid primary care providers in distinguishing dementia with Lewy bodies (DLB) from Alzheimer's disease and from Parkinson's disease with dementia. Differentiating these entities has important treatment implications. DATA SOURCES: A PubMed search was undertaken using the keywords Lewy body dementia, dementia with Lewy bodies, and Lewy body disease. There were no date restrictions. Only articles in the English language were reviewed. References of selected articles were reviewed for additional sources. DATA SELECTION AND EXTRACTION: Initially, 2,967 articles were retrieved. All 3 authors participated in data selection and extraction. Articles were further selected for content specific to epidemiology, clinical presentation, diagnostic studies, treatment, and prognosis. For articles with repetitive information, the most current article was used. This resulted in a total of 62 articles included in the review. DATA SYNTHESIS: Dementia with Lewy bodies is the second leading cause of dementia after Alzheimer's disease. The core symptoms of DLB, including cognitive fluctuations, visual hallucinations, and parkinsonism, may not always be present as a triad, and clinicians may be unaware of associated symptoms. Thus, this diagnosis is frequently missed by primary care providers. Often, DLB is misdiagnosed as Alzheimer's disease, Parkinson's disease, or a primary psychiatric illness. Treatments for DLB include cholinesterase inhibitors and N-methyl-D-aspartate antagonists. Antipsychotics should be avoided or used with caution. CONCLUSIONS: Dementia with Lewy bodies is an often missed diagnosis. Symptoms are often attributed to other disorders. A high clinical suspicion is helpful in accurate diagnosis, and presence of any of the core symptoms should initiate clinical suspicion of DLB. Distinguishing DLB from other disorders has important treatment implications.
OBJECTIVE: The purpose of this review is to aid primary care providers in distinguishing dementia with Lewy bodies (DLB) from Alzheimer's disease and from Parkinson's disease with dementia. Differentiating these entities has important treatment implications. DATA SOURCES: A PubMed search was undertaken using the keywords Lewy body dementia, dementia with Lewy bodies, and Lewy body disease. There were no date restrictions. Only articles in the English language were reviewed. References of selected articles were reviewed for additional sources. DATA SELECTION AND EXTRACTION: Initially, 2,967 articles were retrieved. All 3 authors participated in data selection and extraction. Articles were further selected for content specific to epidemiology, clinical presentation, diagnostic studies, treatment, and prognosis. For articles with repetitive information, the most current article was used. This resulted in a total of 62 articles included in the review. DATA SYNTHESIS: Dementia with Lewy bodies is the second leading cause of dementia after Alzheimer's disease. The core symptoms of DLB, including cognitive fluctuations, visual hallucinations, and parkinsonism, may not always be present as a triad, and clinicians may be unaware of associated symptoms. Thus, this diagnosis is frequently missed by primary care providers. Often, DLB is misdiagnosed as Alzheimer's disease, Parkinson's disease, or a primary psychiatric illness. Treatments for DLB include cholinesterase inhibitors and N-methyl-D-aspartate antagonists. Antipsychotics should be avoided or used with caution. CONCLUSIONS:Dementia with Lewy bodies is an often missed diagnosis. Symptoms are often attributed to other disorders. A high clinical suspicion is helpful in accurate diagnosis, and presence of any of the core symptoms should initiate clinical suspicion of DLB. Distinguishing DLB from other disorders has important treatment implications.
Authors: Keith Edwards; Donald Royall; Linda Hershey; David Lichter; Ann Hake; Martin Farlow; Florence Pasquier; Stewart Johnson Journal: Dement Geriatr Cogn Disord Date: 2007-04-03 Impact factor: 2.959
Authors: J Grace; S Daniel; T Stevens; K K Shankar; Z Walker; E J Byrne; S Butler; D Wilkinson; J Woolford; J Waite; I G McKeith Journal: Int Psychogeriatr Date: 2001-06 Impact factor: 3.878
Authors: Laura Bonanni; Astrid Thomas; Pietro Tiraboschi; Bernardo Perfetti; Sara Varanese; Marco Onofrj Journal: Brain Date: 2008-01-17 Impact factor: 13.501
Authors: M E Tinetti; D I Baker; G McAvay; E B Claus; P Garrett; M Gottschalk; M L Koch; K Trainor; R I Horwitz Journal: N Engl J Med Date: 1994-09-29 Impact factor: 91.245
Authors: C G Ballard; K A Chalmers; C Todd; I G McKeith; J T O'Brien; G Wilcock; S Love; E K Perry Journal: Neurology Date: 2007-05-15 Impact factor: 9.910
Authors: Devesh Tewari; Adrian M Stankiewicz; Andrei Mocan; Archana N Sah; Nikolay T Tzvetkov; Lukasz Huminiecki; Jarosław O Horbańczuk; Atanas G Atanasov Journal: Front Aging Neurosci Date: 2018-02-12 Impact factor: 5.750
Authors: Myrto Stylianou; Nicholas Murphy; Luis R Peraza; Sara Graziadio; Ruth Cromarty; Alison Killen; John T O' Brien; Alan J Thomas; Fiona E N LeBeau; John-Paul Taylor Journal: Clin Neurophysiol Date: 2018-04-03 Impact factor: 3.708
Authors: Daniela D Maltais; Lennon G Jordan; Hoon-Ki Min; Toji Miyagawa; Scott A Przybelski; Timothy G Lesnick; Robert R Reichard; Dennis W Dickson; Melissa E Murray; Kejal Kantarci; Bradley F Boeve; Val J Lowe Journal: J Nucl Med Date: 2020-03-20 Impact factor: 11.082